Influenza Clinical Trial
Official title:
Annual Study of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2005-2006 Formulation)
Verified date | April 2016 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
To describe the safety during Days 0 to 21 following injection of the 2005-2006 formulation
of the inactivated, split-virion influenza vaccine Fluzone in subjects aged 18-59 years and
subjects aged ≥ 60 years.
To describe the immune response (antibodies to hemagglutinin) 21 days following injection of
the 2005-2006 formulation of the inactivated, split-virion influenza vaccine Fluzone, in
subjects aged 18-59 years and subjects aged ≥ 60 years.
To submit remaining available sera to the Center for Biologics Evaluation and Research
(CBER) for further analysis by the Food and Drug Administration (FDA), Center for Disease
Control and Prevention (CDC) and the World Health Organization (WHO) to support selection
and recommendation of antigen strains for subsequent influenza vaccines.
Status | Completed |
Enrollment | 120 |
Est. completion date | March 2007 |
Est. primary completion date | February 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participant aged 18 years or older on the day of inclusion. - Participant able to attend scheduled visits and to comply with the study procedures during the entire duration of the study. - Participant is in reasonably good health as assessed by the investigator. - Participant willing and able to meet protocol requirements. - Participant willing and able to give informed consent. - For a woman, inability to bear a child or negative serum/urine pregnancy test. Exclusion Criteria: - Self-reported allergy to egg proteins, chicken proteins, or one of the constituents of the vaccine, such as thimerosal or formaldehyde. - An acute illness with or without fever (temperature = 99.5°F oral) in the 72 hours preceding enrollment in the trial. - Clinically significant findings in vital signs (including temperature = 99.5°F oral) on review of systems. - Self-reported history of severe adverse event to any influenza vaccine. - Laboratory-confirmed influenza infection or vaccination against influenza in the 6 months preceding enrollment in the study. - Any vaccination in the 14 days preceding enrollment in the study or scheduled between Visit 1 and Visit 3. - Vaccination planned in the 4 weeks following any trial vaccination. - Participation in any other interventional drug or vaccine trial within the 30 days preceding or during enrollment into this study. - Immunocompromising or immunosuppressive therapy (including systemic steroid use for 2 weeks or more), cancer chemotherapy, or radiation therapy at the time of enrollment, planned during the period of this study, or at any time within the past 6 months. - Receipt of blood or blood products within the 3 months preceding enrollment in the study. - Diabetes mellitus requiring pharmacological control. - Any condition that in the opinion of the Investigator posed a health risk to the subject if enrolled or interfered with the evaluation of the vaccine. - Person deprived of freedom by an administrative or court order (having legal or medical guardian). - For women of childbearing potential, a positive urine pregnancy test, breast feeding, or not using a medically approved form of contraception for the duration of the trial. - Current abuse of alcohol or drug addiction that interfered with the subject's ability to comply with trial procedures. - Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sanofi Pasteur, a Sanofi Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percentage of Participants With = 40 Serum Hemagglutination Inhibition Antibody Titers Post-vaccination. | Seroprotection: Percentage of participants with = 40 serum hemagglutination inhibition antibody titers 21 days post-vaccination. | 21 Days post-vaccination | No |
Other | Percentage of Participants With a = 4-fold Increase in Serum Hemagglutination Inhibition Antibody Titers Post-vaccination | Seroconversion: percentage of participants with at least a 4-fold increase in serum hemagglutination inhibition antibody titers at 21 days post-vaccination. | Day 21 post-vaccination | No |
Primary | Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Fluzone® Vaccination | Day 0 to 3 post-vaccination | Yes | |
Primary | Geometric Mean Titers (GMTs) of Hemagglutination Antibodies Before and After Fluzone® Vaccination | GMTs and their 95% Confidence Intervals are presented for each of the 3 antigens in Fluzone® vaccine (2005-2006 Formulation) | 21 days post-vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |